CD274 and esophageal squamous cell carcinoma: Prior economic evidence indicated that PD-1 inhibitors were potentially more sensitive to PD-L1-positive ESCC patients against overall population (Zhu et al., 2022a; Liu et al., 2022; Shao et al., 2022).